Liver damage drug study: no cure, just knowledge

NCT ID NCT07401862

First seen Feb 14, 2026 · Last updated May 12, 2026 · Updated 16 times

Summary

This study looks at how the drug eloralintide is processed by the body in people with mild, moderate, or severe liver damage compared to those with healthy livers. About 36 adults will receive a single shot and stay at a clinic for 5 nights. The goal is to understand safety and drug levels, not to treat liver disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • American Research Corporation

    RECRUITING

    San Antonio, Texas, 78215, United States

    Contact Phone: •••-•••-••••

    Contact

  • CRU Early Phase Unit

    NOT_YET_RECRUITING

    Kistarcsa, H-2143, Hungary

    Contact Phone: •••-•••-••••

    Contact

  • Orlando Clinical Research Center

    RECRUITING

    Orlando, Florida, 32809, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.